Micropos Medical (MPOS) investor relations material

Executive summary

• Net sales for the year increased by 113% to 8,126 Tkr compared to 3,824 Tkr the previous year.

• Result after financial items was -21,705 Tkr, a slight improvement from -21,868 Tkr last year.

• The company achieved clinical acceptance for ASBRT with Raypilot System, with about 400 patients treated and strong customer satisfaction.

• Eight new Raypilot Systems were installed during the year, with two installations in the US, expanding international presence.

• The fourth quarter focused on strengthening customer relations, advancing clinical studies, and regulatory progress.

Financial highlights

• Net sales for Q4 were 1,354 Tkr, down from 1,741 Tkr in Q4 last year.

• Full-year net sales reached 8,126 Tkr, up 113% year-over-year.

• Result after financial items for Q4 was -6,093 Tkr (Q4 2024: -4,577 Tkr); full-year result was -21,705 Tkr (-21,868 Tkr in 2024).

• Equity at year-end was 13,729 Tkr (10,123 Tkr last year); soliditet improved to 72% (63%).

• Cash flow for the year was 1,871 Tkr (1,951 Tkr in 2024); cash and bank at year-end was 9,841 Tkr (7,968 Tkr in 2024).

Outlook and guidance

• The company expects continued growth as SBRT becomes more established, especially in markets like the UK, Spain, Italy, Austria, and Switzerland.

• Capital injection will be needed in the first half of 2026 due to slow ramp-up in patient numbers.

• Ongoing efforts to increase awareness and adoption of ASBRT and Raypilot System among patients and clinicians.